Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2014 | Research

Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer

Authors: Mitsuro Kanda, Shuji Nomoto, Hisaharu Oya, Dai Shimizu, Hideki Takami, Soki Hibino, Ryoji Hashimoto, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Tsutomu Fujii, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Abstract

Background

Gastric cancer (GC) remains to have a poor prognosis via diverse process of cancer progression. Dihydropyrimidinase-like 3 (DPYSL3) is a cell adhesion molecule that has been reported to be involved in the metastatic process of tumor cells. The aim of this study was to identify a novel clinically-relevant biomarker of GC.

Methods

Expression analysis of DPYSL3 mRNA and protein levels was conducted using GC cell lines and 238 pairs of surgically resected gastric tissues. Correlations between expression status of DPYSL3 and clinicopathological parameters were investigated.

Results

DPYSL3 mRNA expression levels positively correlated with those of potentially interacting genes (VEGF, FAK and EZR) in GC cell lines. GC tissues from tumors with distant metastases (stage IV cancer) showed elevated expression levels of DPYSL3 mRNA. The DPYSL3 staining intensity in immunochemical staining was consistent with the mRNA expression patterns in GC tissues. High DPYSL3 mRNA expression in GCs was significantly associated with more malignant phenotypes and was an independent prognostic factor. Moreover, patients with high DPYSL3 mRNA expression had a significantly shorter recurrence free survival after curative resection. In subgroup analysis based on tumor histology, similar tendency was observed between patients with differentiated and undifferentiated GCs.

Conclusions

Expression status of DPYSL3 in GC tissues may represent a promising biomarker for the malignant behavior of GC.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed

Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, Lee M, Rha SY, Huang D, Liem N, Yeoh KG, Yong WP, Teh BT, Tan P: Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut. 2013, 62: 22-33. 10.1136/gutjnl-2011-301113.CrossRefPubMed

Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT: Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013, 14: e535-547. 10.1016/S1470-2045(13)70436-4.CrossRefPubMed

Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ: Gastric cancer. Lancet. 2009, 374: 477-490. 10.1016/S0140-6736(09)60617-6.PubMedCentralCrossRefPubMed

Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006, 24: 2903-2909. 10.1200/JCO.2005.05.0245.CrossRefPubMed

Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003, 3: 55-63. 10.1038/nrc967.CrossRefPubMed

Kanda M, Nomoto S, Okamura Y, Hayashi M, Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S, Nakao A: Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma. Mol Carcinog. 2011, 50: 571-579. 10.1002/mc.20735.CrossRefPubMed

Gonzalez CA, Agudo A: Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 2012, 130: 745-753. 10.1002/ijc.26430.CrossRefPubMed

Janjigian YY, Kelsen DP: Genomic dysregulation in gastric tumors. J Surg Oncol. 2013, 107: 237-242. 10.1002/jso.23263.CrossRefPubMed

10.

Jang BG, Kim WH: Molecular pathology of gastric carcinoma. Pathobiology. 2011, 78: 302-310. 10.1159/000321703.CrossRefPubMed

11.

Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM: Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature. 1995, 376: 509-514. 10.1038/376509a0.CrossRefPubMed

12.

Matsuo T, Stauffer JK, Walker RL, Meltzer P, Thiele CJ: Structure and promoter analysis of the human unc-33-like phosphoprotein gene. E-box required for maximal expression in neuroblastoma and myoblasts. J Biol Chem. 2000, 275: 16560-16568. 10.1074/jbc.M001312200.CrossRefPubMed

13.

BioGPS..,http://biogps.org/

14.

Gao X, Pang J, Li LY, Liu WP, Di JM, Sun QP, Fang YQ, Liu XP, Pu XY, He D, Li MT, Su ZL, Li BY: Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene. 2010, 29: 4555-4566. 10.1038/onc.2010.213.CrossRefPubMed

15.

Kawahara T, Hotta N, Ozawa Y, Kato S, Kano K, Yokoyama Y, Nagino M, Takahashi T, Yanagisawa K: Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex. PLoS One. 2013, 8: e79654-10.1371/journal.pone.0079654.PubMedCentralCrossRefPubMed

16.

Kanda M, Nomoto S, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A: Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. J Surg Oncol. 2008, 98: 190-196. 10.1002/jso.21095.CrossRefPubMed

17.

Sobin LH, Gospodarowicz MK, Wittekind C: International Union Against Cancer, TNM Classification of Malignant Tumors. 2009, Wiley-Blackwell, New York

18.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357: 1810-1820. 10.1056/NEJMoa072252.CrossRefPubMed

19.

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011, 29: 4387-4393. 10.1200/JCO.2011.36.5908.CrossRefPubMed

20.

Kanda M, Nomoto S, Okamura Y, Nishikawa Y, Sugimoto H, Kanazumi N, Takeda S, Nakao A: Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int J Oncol. 2009, 35: 477-483. 10.3892/ijo_00000448.CrossRefPubMed

21.

Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S, Kodera Y: Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. J Exp Clin Cancer Res. 2013, 32: 65-PubMedCentralCrossRefPubMed

22.

Shimizu D, Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Suenaga M, Inokawa Y, Hishida M, Takano N, Nishikawa Y, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y: Identification of intragenic methylation in the TUSC1 gene as a novel prognostic marker of hepatocellular carcinoma. Oncol Rep. 2014, 31: 1305-1313.PubMed

23.

Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, Asai M, Fujii T, Sugimoto H, Kodera Y: Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol. 2014, 44: 44-52.PubMed

24.

Loupy A, Hill GS, Suberbielle C, Charron D, Anglicheau D, Zuber J, Timsit MO, Duong JP, Bruneval P, Vernerey D, Empana JP, Jouven X, Nochy D, Legendre CH: Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant. 2011, 11: 56-65. 10.1111/j.1600-6143.2010.03364.x.CrossRefPubMed

25.

Kanda M, Shimizu D, Nomoto S, Hibino S, Oya H, Takami H, Kobayashi D, Yamada S, Inokawa Y, Tanaka C, Fujii T, Sugimoto H, Koike M, Fujiwara M, Kodera Y: Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer. J Surg Oncol. 2014, 110: 136-144.CrossRefPubMed

26.

Hibino S, Kanda M, Oya H, Takami H, Shimizu D, Nomoto S, Hishida M, Niwa Y, Koike M, Yamada S, Nishikawa Y, Asai M, Nakayama G, Fujii T, Sugimoto H, Fujiwara M, Kodera Y: Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus. Oncol Rep. 2014, 31: 693-700.PubMed

27.

Frame MC, Patel H, Serrels B, Lietha D, Eck MJ: The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol. 2010, 11: 802-814. 10.1038/nrm2996.CrossRefPubMed

28.

Fehon RG, McClatchey AI, Bretscher A: Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol. 2010, 11: 276-287. 10.1038/nrm2866.PubMedCentralCrossRefPubMed

29.

Srivastava J, Elliott BE, Louvard D, Arpin M: Src-dependent ezrin phosphorylation in adhesion-mediated signaling. Mol Biol Cell. 2005, 16: 1481-1490. 10.1091/mbc.E04-08-0721.PubMedCentralCrossRefPubMed

30.

Sakaguchi T, Watanabe A, Sawada H, Yamada Y, Tatsumi M, Fujimoto H, Emoto K, Nakano H: Characteristics and clinical outcome of proximal-third gastric cancer. J Am Coll Surg. 1998, 187: 352-357. 10.1016/S1072-7515(98)00191-4.CrossRefPubMed

31.

Vogiatzi P, Vindigni C, Roviello F, Renieri A, Giordano A: Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol. 2007, 211: 287-295. 10.1002/jcp.20982.CrossRefPubMed

32.

Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, Hashimoto R, Suenaga M, Inokawa Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y: Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer. 2014, Epub ahead of print, PubMed PMID: 24695972

33.

Wang YY, Li L, Zhao ZS, Wang YX, Ye ZY, Tao HQ: L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients. J Exp Clin Cancer Res. 2013, 32: 66-PubMedCentralCrossRefPubMed

Title: Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer
Authors: Mitsuro Kanda
Shuji Nomoto
Hisaharu Oya
Dai Shimizu
Hideki Takami
Soki Hibino
Ryoji Hashimoto
Daisuke Kobayashi
Chie Tanaka
Suguru Yamada
Tsutomu Fujii
Goro Nakayama
Hiroyuki Sugimoto
Masahiko Koike
Michitaka Fujiwara
Yasuhiro Kodera
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-014-0066-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Blockade of CXCL12/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway

miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST

Dual effect of oxidative stress on leukemia cancer induction and treatment

Parathyroid hormone-related protein serves as a prognostic indicator in oral squamous cell carcinoma

IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis

Reciprocal regulation of PCGEM1 and miR-145promote proliferation of LNCaP prostate cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer